14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.65 Wednesday, 24th Apr 2024 ADAP stock ended at $1.08. This is 5.26% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 7.48% from a day low at $1.07 to a day high of $1.15.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Jul 07, 2023 $0.93 $0.94 $0.90 $0.90 1 013 018
Jul 06, 2023 $0.94 $0.96 $0.92 $0.93 531 925
Jul 05, 2023 $0.93 $0.98 $0.93 $0.94 670 523
Jul 03, 2023 $0.93 $0.94 $0.92 $0.93 294 288
Jun 30, 2023 $0.94 $0.96 $0.91 $0.93 809 640
Jun 29, 2023 $0.90 $0.96 $0.90 $0.94 676 286
Jun 28, 2023 $0.90 $0.97 $0.89 $0.91 1 127 872
Jun 27, 2023 $0.92 $0.93 $0.88 $0.90 1 257 179
Jun 26, 2023 $0.94 $0.95 $0.91 $0.92 1 123 764
Jun 23, 2023 $0.98 $0.98 $0.94 $0.95 1 032 284
Jun 22, 2023 $0.99 $1.00 $0.96 $0.99 1 044 780
Jun 21, 2023 $1.02 $1.03 $0.91 $1.01 2 413 303
Jun 20, 2023 $1.01 $1.07 $0.99 $1.04 1 090 474
Jun 16, 2023 $1.02 $1.03 $0.97 $1.02 1 324 671
Jun 15, 2023 $1.01 $1.06 $1.01 $1.01 812 980
Jun 14, 2023 $1.00 $1.06 $1.00 $1.04 816 820
Jun 13, 2023 $1.04 $1.06 $1.00 $1.01 1 096 815
Jun 12, 2023 $0.98 $1.05 $0.97 $1.04 1 144 870
Jun 09, 2023 $1.02 $1.04 $0.96 $0.99 1 024 127
Jun 08, 2023 $1.04 $1.06 $0.98 $1.01 1 234 139
Jun 07, 2023 $1.08 $1.08 $1.02 $1.04 1 220 467
Jun 06, 2023 $1.05 $1.12 $0.99 $1.08 1 869 267
Jun 05, 2023 $1.10 $1.14 $1.01 $1.04 1 069 828
Jun 02, 2023 $1.12 $1.14 $1.08 $1.08 1 075 578
Jun 01, 2023 $1.04 $1.12 $1.03 $1.09 700 752
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT